{"filing":{"accession_number":"0001628280-26-058126","cik":"0002007191","ticker":"TLPPF","company_name":"Telix Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-08-19","report_date":"2026-06-30","primary_document":"tlx-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/tlx-20260630.htm"},"events":[{"id":28645,"run_id":26210,"accession_number":"0001628280-26-058126","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a half-year financial results announcement for Telix Pharmaceuticals for the period ended June 30, 2026. The exhibit discloses key financial metrics including revenue of US$477 million (up 22% year-over-year), gross margin of 55%, adjusted EBITDA of US$52 million, and profit after tax of US$38 million, along with segment performance and operational milestones. This is a discrete earnings event, not a periodic financial report itself, and would materially affect investor assessment of the company's financial performance and commercial execution.","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-08-19","form":"6-K","submitted_at":null,"items":[{"id":30657,"accession_number":"0001628280-26-058126","item_number":"EX-99.3","item_title":"announcement.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a half-year financial results announcement for Telix Pharmaceuticals for the period ended June 30, 2026. The exhibit discloses key financial metrics including revenue of US$477 million (up 22% year-over-year), gross margin of 55%, adjusted EBITDA of US$52 million, and profit after tax of US$38 million, along with segment performance and operational milestones. This is a discrete earnings event, not a periodic financial report itself, and would materially affect investor assessment of the company's financial performance and commercial execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T10:05:05.928177+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30655,"accession_number":"0001628280-26-058126","item_number":"EX-99.1","item_title":"presentation.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a presentation accompanying Telix's H1 2026 Interim Results, disclosed on August 20, 2026. The document contains interim financial statements (H1 2026 Income Statement, segment results for Precision Medicine and TMS), revenue metrics, EBITDA, cash position, and forward guidance for FY 2026. It is a periodic interim financial report, not a discrete event or earnings release press release, and should be classified as such for deferred processing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T10:05:05.928177+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-08-19"},{"id":30656,"accession_number":"0001628280-26-058126","item_number":"EX-99.2","item_title":"a20260820telixhy26append.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is Telix's Appendix 4D and Interim Report for the half-year ended June 30, 2026, filed with the ASX under Listing Rule 4.2A. It comprises the company's interim financial statements, directors' report, and auditor's review for a six-month period, not a discrete event announcement. The document explicitly states it is \"the half-year information given to the ASX under Listing Rule 4.2A\" and includes consolidated interim financial statements prepared in accordance with IFRS. This is a periodic interim financial report, distinct from an earnings release press announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T10:05:05.928177+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-08-19"},{"id":30657,"accession_number":"0001628280-26-058126","item_number":"EX-99.3","item_title":"announcement.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a half-year financial results announcement for Telix Pharmaceuticals for the period ended June 30, 2026. The exhibit discloses key financial metrics including revenue of US$477 million (up 22% year-over-year), gross margin of 55%, adjusted EBITDA of US$52 million, and profit after tax of US$38 million, along with segment performance and operational milestones. This is a discrete earnings event, not a periodic financial report itself, and would materially affect investor assessment of the company's financial performance and commercial execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T10:05:05.928177+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-08-19"},{"id":30658,"accession_number":"0001628280-26-058126","item_number":"EX-99.4","item_title":"tlx-20260630_d2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is Telix's interim financial report for the half-year ended June 30, 2026, presenting consolidated statements of comprehensive income, segment results, and detailed financial analysis. The document explicitly states \"Half-year ended June 30, 2026\" and \"June 30, 2025\" throughout, and includes full financial statements with revenue, cost of sales, operating expenses, and segment breakdowns. This is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete earnings-release event, and should be classified as such for deferred processing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T10:05:05.928177+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-08-19"}]}